

SYNTHESIS AND BIOASSAY STUDIES OF CATIONIC PORPHYRINS FOR
GENE TRANSFECTION DELIVERY

KIEW SIAW FUI

A thesis submitted in fulfillment of the
requirements for the award of the degree of
Master of Science (Chemistry)

Faculty of Science
Universiti Teknologi Malaysia

JANUARY 2013

To my beloved father, mother, brothers and dearest sister

ACKNOWLEDGEMENT

First, I would like to express my deeply appreciation to my supervisor, Dr. Mohd Bakri Bin Bakar for his valuable knowledge, patient guidance, enthusiastic support and friendship towards the success of completion of this study. Besides, I am very thankful to my co-supervisor, Dr. Razauden Mohamed Zulkifli for his constructive advices, encouragement and generosity during the planning and development of this research work.

I would also like to acknowledge the laboratory staff Pn Zahratulain, En Azmi, Pn Nasrena, Pn Suhaini, En Amin, En Rasyidi, En Azidy, En Rahim, Ms Norsyuhada and others for their technical support and assistance with the collection of my data.

Special thanks to Ministry of Higher Education Malaysia (FRGS vot 78554), MyMaster and Universiti Teknologi Malaysia (UTM) for the financial support as well as the facilities provided by UTM.

My sincere appreciation also extends to all my colleagues and friends; Helmi, Sayang, Nurhafizah, Ermi, Azhana, Syahda, Asita, Zuhairi, Ke Xin and Wen Yee for their helps and willingness to share useful knowledge. Last but not least, I would like to thank my family for their support and motivation both in spirit and financial.

ABSTRACT

Porphyrins are stable aromatic tetrapyrrolic macromolecules found in many natural products such as hemin, chlorophylls and vitamin B₁₂. Interaction ability of cationic porphyrins with nucleic acid and their fluorescent properties for location identification in cellular domain have promoted their uses as potential gene vectors for gene therapy. In this study, basic cationic porphyrins bearing four positive charges were synthesized. Besides, amphiphilic porphyrins anchored with both hydrophobic and hydrophilic moieties were prepared to facilitate membrane penetration and to give a higher cellular uptake. Polyamidoamine (PAMAM)-porphyrin conjugate was also prepared to produce a complex with higher transfection level but with low toxicity. Adler-Longo condensation method was mainly used to synthesize these cationic porphyrin precursors. All cationic porphyrins were obtained in high yield. All of the compounds were characterized using ¹H-NMR, ¹³C-NMR, ultraviolet (UV) and infrared (IR) spectroscopies. Cytotoxicity and cellular uptake of all cationic compounds were tested on Chinese Hamster Ovary (CHO) cells to evaluate their potential uses as gene carriers. Results revealed that all porphyrins show relatively low toxicity towards the cell even at high concentration (100 μM). The 5,10,15,20-tetrakis(*N*-methyl-4-pyridyl)porphyrin and two amphiphilic cationic porphyrins of 5-hexyl-10,15,20-tris(*N*-methyl-4-pyridyl)porphyrin and 5-propyl-10,15,20-tris(*N*-methyl-4-pyridyl)porphyrin which contain three positive charges on the periphery show the highest cellular uptake. It was also found that the amphiphilic *cis*-porphyrins of 5,10-dipropyl-15,20-bis(*N*-methyl-4-pyridyl)porphyrin and 5,10-dihexyl-15,20-bis(*N*-methyl-4-pyridyl)porphyrin exhibited higher cellular uptake compared to their *trans*-isomers, 5,15-dipropyl-10,20-bis(*N*-methyl-4-pyridyl)porphyrin and 5,15-dihexyl-10,20-bis(*N*-methyl-4-pyridyl)porphyrin.

ABSTRAK

Porfirina adalah makromolekul aromatik yang stabil dan boleh dijumpai dalam banyak sebatian semula jadi seperti hemin, klorofil dan vitamin B₁₂. Keupayaan porfirina kationik untuk berinteraksi dengan acid nukleik dan sifat pendarfluor porfirina yang dapat menentukan lokasi vektor di dalam sel menyebabkan ianya berpotensi untuk digunakan sebagai vektor gen bagi aplikasi terapi gen. Dalam kajian ini, porfirina kationik asas yang mengandungi empat cas positif telah disintesis. Selain itu, porfirina amfifilik yang bersifat hidrofobik dan hidrofilik telah disediakan untuk memudahkan penetrasi membran dan meningkatkan pengambilan bahan oleh sel. Konjugat poliamidoamina (PAMAM)-porfirina juga disediakan untuk menghasilkan kompleks yang mempunyai tahap transfeksi yang lebih tinggi dengan ketoksikan yang rendah. Kaedah kondensasi Adler-Longo digunakan untuk mensintesis pelbagai bahan mula porfirina kationik. Semua porfirina kationik diperolehi dengan hasil yang tinggi. Semua sebatian telah dicirikan dengan menggunakan spektroskopi ¹H-RMN, ¹³C-RMN, ultralembayung (UL) dan inframerah (IM). Kajian toksisiti dan pengambilan sel untuk semua sebatian kationik tersebut dilakukan dengan menggunakan sel Ovari Hamster Cina (CHO) untuk menilai potensinya sebagai pembawa gen. Keputusan kajian mendapati bahawa semua porfirina menunjukkan ketoksikan yang agak rendah walaupun pada kepekatan yang tinggi (100 µM). 5,10,15,20-Tetrakis(*N*-metil-4-piridil)porfirina dan dua porfirina kationik amfifilik, 5-heksil-10,15,20-tris(*N*-metil-4-piridil)porfirina dan 5-propil-10,15,20-tris(*N*-metil-4-piridil)porfirina yang mengandungi tiga cas positif menunjukkan pengambilan selular yang tinggi. Dapatan kajian juga menunjukkan *cis*-porfirina amfifilik, 5,10-dipropil-15,20-bis(*N*-metil-4-pyridil)porfirina dan 5,10-diheksil-15,20-bis(*N*-metil-4-piridil)porfirina menunjukkan pengambilan selular yang lebih tinggi berbanding dengan *trans*-isomer, 5,15-dipropil-10,20-bis(*N*-metil-4-piridil)porfirina and 5,15-diheksil-10,20-bis(*N*-metil-4-piridil)porfirina.

TABLE OF CONTENTS

CHAPTER	TITLE	PAGE
	TITLE	i
	DECLARATION	ii
	DEDICATION	iii
	ACKNOWLEDGEMENTS	iv
	ABSTRACT	v
	ABSTRAK	vi
	TABLE OF CONTENT	vii
	LIST OF TABLES	xii
	LIST OF FIGURES	xiii
	LIST OF SCHEMES	xv
	LISTS OF ABBREVIATIONS	xvii
	LIST OF APPENDICES	xx
1	INTRODUCTION	1
	1.1 Background of the Study	1
	1.2 Problem Statement	4
	1.3 Objectives of the Study	5
	1.4 Scope of the Study	5
	1.5 Significance of the Study	6
2	LITERATURE REVIEW	7
	2.1 Porphyrins	7
	2.1.1 The Electronic Structure and Properties	8

	of Porphyrins	
	2.1.2 NMR Spectroscopy of Porphyrins	8
	2.1.3 UV Spectroscopy of Porphyrins	9
2.2	Synthesis of Porphyrins	11
	2.2.1 Condensation of Pyrrole and Aldehydes	12
	2.2.2 Synthetic Transformation of Porphyrins	18
	2.2.3 Metallation of Porphyrin	19
2.3	Cationic Porphyrins	20
2.4	Amphiphilic Porphyrins	25
2.5	Cationic Dendrimer-Porphyrin Conjugates	29
	2.5.1 Polyamidoamine (PAMAM) Dendrimer	29
2.6	Gene Therapy	34
3	RESULTS AND DISCUSSION	36
3.1	Synthesis of Symmetrical Porphyrins	37
	3.1.1 Synthesis of 5,10,15,20-tetraphenyl porphyrin (6)	37
	3.1.2 Synthesis of 5,10,15,20-tetrakis(4-acetamidophenyl)porphyrin (38)	39
	3.1.3 Synthesis of 5,10,15,20-tetrakis(4-pyridyl) porphyrin (15)	43
3.2	Synthesis of Asymmetrical Porphyrins	44
	3.2.1 Synthesis of 5-propyl-10,15,20-tris(4-pyridyl)porphyrin (39)	46
	3.2.2 Synthesis of 5-hexyl-10,15,20-tris(4-pyridyl)porphyrin (43)	49
	3.2.3 Synthesis of 5-(carboxyphenyl)-10,15,20-tris(4-pyridyl)porphyrin (53)	51
3.3	Synthesis of PAMAM G ₄ -Porphyrin Conjugate (54)	56
3.4	Synthesis of Basic Cationic Porphyrins	59
	3.4.1 Synthesis of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin (17)	59

3.5	Synthesis of Amphiphilic Cationic Porphyrins	62
3.5.1	Synthesis of 5,15-dipropyl-10,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (57)	63
3.5.2	Synthesis of 5,10-dipropyl-15,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (58)	64
3.5.3	Synthesis of 5-propyl-10,15,20-tris (<i>N</i> -methyl-4-pyridyl)porphyrin (59)	65
3.5.4	Synthesis of 5,10,15-trihexyl-20-(<i>N</i> -methyl -4-pyridyl)porphyrin (60)	65
3.5.5	Synthesis of 5,15-dihexyl-10,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (61)	66
3.5.6	Synthesis of 5,10-dihexyl-15,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (62)	67
3.5.7	Synthesis of 5-hexyl-10,15,20-tris (<i>N</i> -methyl-4-pyridyl)porphyrin (63)	68
3.6	Synthesis of Cationic PAMAM G ₄ -Porphyrin Conjugate (64)	69
3.7	Cytotoxicity of Porphyrin Derivatives on CHO Cells	70
3.8	Cellular Uptake of Porphyrin Derivatives	74
4	EXPERIMENTAL	80
4.1	General Instruments and Apparatus	80
4.2	Chemicals and Reagents	80
4.3	Synthesis of Symmetrical Porphyrins	81
4.3.1	Synthesis of 5,10,15,20-tetraphenyl porphyrin (6)	81
4.3.2	Synthesis of 5,10,15,20-tetrakis(4-acetami dophenyl)porphyrin (38)	82
4.3.3	Synthesis of 5,10,15,20-tetrakis(4-pyridyl) porphyrin (15)	83
4.4	Synthesis of Asymmetrical Porphyrins	83
4.4.1	Synthesis of 5-propyl-10,15,20-tris porphyrin (39)	83

4.4.2	Synthesis of 5-hexyl-10,15,20-tris (4-pyridyl)porphyrin (43)	85
4.4.3	Synthesis of 5-(methoxycarbonylphenyl) -10,15,20-tris(4-pyridyl)porphyrin (48)	88
4.4.4	Synthesis of 5-(carboxyphenyl)-10,15,20 -tris(4-pyridyl)porphyrin (53)	90
4.5	Synthesis of PAMAM G ₄ -Porphyrin Conjugate (54)	91
4.6	Synthesis of Basic Cationic Porphyrins	92
4.6.1	Synthesis of 5,10,15,20-tetrakis(<i>N</i> -methyl -4-pyridyl)porphyrin (17)	92
4.6.2	Synthesis of 5,10-bis(<i>N</i> -methyl-4-pyridyl) -15,20-bis(4-pyridyl)porphyrin or 5,15-bis (<i>N</i> -methyl-4-pyridyl)-10,20-bis(4-pyridyl) porphyrin (55)	92
4.6.3	Synthesis of 5,10,15-tris(<i>N</i> -methyl-4- pyridyl)-20-(4-pyridyl)porphyrin (56)	93
4.7	Synthesis of Amphiphilic Cationic Porphyrins	94
4.7.1	Synthesis of 5,15-dipropyl-10,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (57)	94
4.7.2	Synthesis of 5,10-dipropyl-15,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (58)	94
4.7.3	Synthesis of 5-propyl-10,15,20-tris (<i>N</i> -methyl-4-pyridyl)porphyrin (59)	95
4.7.4	Synthesis of 5,10,15-trihexyl-20- (<i>N</i> -methyl-4-pyridyl)porphyrin (60)	96
4.7.5	Synthesis of 5,15-dihexyl-10,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (61)	96
4.7.6	Synthesis of 5,10-dihexyl-15,20-bis (<i>N</i> -methyl-4-pyridyl)porphyrin (62)	97
4.7.7	Synthesis of 5-hexyl-10,15,20-tris (<i>N</i> -methyl-4-pyridyl)porphyrin (63)	98
4.8	Synthesis of Cationic PAMAM G ₄ -Porphyrin Conjugate (64)	98

4.9	Bioactivity Studies	99
4.9.1	Chemical and Instrumentation	99
4.9.2	Cell Culture and Subculture	100
4.9.3	Cytotoxicity or MTT Assay	101
4.9.3.1	Preparation of MTT Solution and Cytotoxicity Assay Flow Chart	101
4.9.4	Cellular Uptake of Porphyrin Derivatives	104
5	CONCLUSIONS AND SUGGESTIONS	105
5.1	Conclusions	105
5.2	Suggestion for Future Work	106
	REFERENCES	107
	APPENDICES	115
	LIST OF PUBLICATIONS	209

LIST OF TABLES

TABLE NO.	TITLE	PAGE
3.1	Qualitative cellular uptake efficiency of porphyrin derivatives with different distribution of substituents	77

LIST OF FIGURES

FIGURE NO.	TITLE	PAGE
1.1	Structure of porphyrin (1), chlorophyll (2) and hemin (3)	1
1.2	Gene therapy	3
2.1	Basic structure of porphyrin	8
2.2	UV-Vis Q band spectra of metal free porphyrin	10
2.3	UV-Vis Q band spectra for metalloporphyrin	11
2.4	<i>meso</i> -Tetrakis(4- <i>N,N,N</i> -trimethylanilinium)porphyrin (18)	22
2.5	<i>meso</i> -Substituted porphyrins (19) and β -substituted porphyrins (20) with same charge position	23
2.6	<i>meso</i> -Tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin (17) and <i>meso</i> -Tetrakis(<i>N</i> -methyl-2-pyridyl)porphyrin (21)	23
2.7	<i>meso</i> -Substituted porphyrin (22) and sapphyrin (23)	24
2.8	<i>meso</i> -Tetrakis(4-sulfonatophenyl)porphyrin (24)	24
2.9	<i>meso</i> -Substituted cationic porphyrins	27
2.10	Porphyrin (27) with two positive charges and porphyrin (28) with four positive charges	28
2.11	Porphyrin (29) and porphyrin (30)	28
2.12	Structure of polyethylenimine (31) and polyamidoamine (32)	29
3.1	¹ H NMR spectrum of monoalkylated porphyrin	42
3.2	Cell viability (%) versus various concentrations of porphyrins compared with triton® X-100	72
3.3	Endocytosis process of cell and phospholipid bilayer	74
3.4	Cellular uptakes of porphyrin derivatives under inverted fluorescence microscope with 100X magnification.	77

4.1	General flow chart of cytotoxicity assay	102
4.2	Calculation formulas for percentage of cell inhibition and cell growth	102
4.3	Experimental design for 96 wells microplate	103
4.4	General flow chart for cellular uptake of porphyrin derivatives	104

LIST OF SCHEMES

SCHEME NO.	TITLE	PAGE
2.1	Synthesis of tetraphenylporphyrin (6)	12
2.2	Synthesis of porphyrin (9)	13
2.3	One-flask synthesis of <i>meso</i> -substituted dipyrromethanes (10)	13
2.4	One-flask synthesis of a bis-dipyrromethanes (12)	14
2.5	Six porphyrins formed from mixed condensation	14
2.6	Synthesis of <i>trans</i> -substituted porphyrins using four types of dipyrromethanes	15
2.7	MacDonald 2+2 Condensation	16
2.8	“2+2” route to ABCD-porphyrins	16
2.9	“3+1” approach to <i>cis</i> -A ₂ -substituted porphyrin	17
2.10	Direct synthesis of tripyrrane	17
2.11	Synthesis of A ₃ - and A ₂ B-type porphyrins via S _N Ar reactions	18
2.12	Preparation of formylated porphyrin <i>via</i> Vilsmeier reaction	19
2.13	Bromination of <i>meso</i> -tetramesitylporphyrin	19
2.14	Metallation of porphyrin	20
2.15	Synthetic route of TMPyP4 (17)	21
2.16	Synthesis ethylenediamine (EDA) core PAMAM	30
2.17	Schematic representations of PAMAM-TAMCPP conjugate (37) and structure of PAMAM G ₄	33
3.1	Synthesis of 5,10,15,20-tetraphenylporphyrin (6)	37
3.2	Synthesis of 5,10,15,20-tetrakis(4-acetamidophenyl) porphyrin (38)	39
3.3	Synthesis of cationic porphyrin (18)	42

3.4	Synthesis of 5,10,15,20-tetrakis(4-pyridyl)porphyrin (15)	43
3.5	Attempted synthesis of dipyrromethanes (8)	45
3.6	Synthesis of 5-propyl-10,15,20-tris(4-pyridyl)porphyrin (39) and its derivatives	46
3.7	Synthesis of 5-hexyl-10,15,20-tris(4-pyridyl)porphyrin (43) and its derivatives	50
3.8	Synthesis of 5-(methoxycarbonylphenyl)-10,15,20-tris(4-pyridyl) porphyrin (48) and its derivatives	52
3.9	Synthesis of 5-(carboxyphenyl)-10,15,20-tris(4-pyridyl) porphyrin (53)	55
3.10	Synthesis of PAMAM G ₄ -porphyrin conjugate (54)	57
3.11	Synthesis of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl) porphyrin (17)	60
3.12	Synthesis of 5,10-bis(<i>N</i> -methyl-4-pyridyl)-15,20-bis(4-pyridyl)porphyrin (55a) or 5,15-bis(<i>N</i> -methyl-4-pyridyl)-10,20-bis(4-pyridyl)porphyrin (55b) and 5,10,15-tris(<i>N</i> -methyl-4-pyridyl)-20-(4-pyridyl)porphyrin (56)	61
3.13	Synthesis of 5,15-dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (57)	63
3.14	Synthesis of 5,10-dipropyl-15,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (58)	64
3.15	Synthesis of 5-propyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl) porphyrin (59)	65
3.16	Synthesis of 5,10,15-trihexyl-20-(<i>N</i> -methyl-4-pyridyl) porphyrin (60)	66
3.17	Synthesis of 5,15-dihexyl-10,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (61)	67
3.18	Synthesis of 5,10-dihexyl-15,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (62)	68
3.19	Synthesis of 5-hexyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl) porphyrin (63)	68
3.20	Synthesis of cationic PAMAM G ₄ -porphyrin conjugate	70
3.21	Formation of purple formazan (66) by metabolically active cell	70

LIST OF ABBREVIATIONS

ArCHO	-	Aromatic aldehyde
ANOVA	-	Analysis of variance
BF ₃ .O(Et) ₂	-	Boron trifluoride etherate
br	-	Broad
¹³ C	-	Carbon-13
CHO	-	Chinese Hamster Ovary
COSY	-	H-H correlation spectroscopy
CSCl ₂	-	Thiophosgene
d	-	Doublet
DCC	-	Dicyclohexylcarbodiimide
dd	-	Doublet of doublet
DDQ	-	2,3-Dichloro-5,6-dicyano- <i>p</i> -benzoquinone
DiTMPyP	-	5,10-Bis(<i>N</i> -methyl-4-pyridyl)-15,20-bis(4-pyridyl)porphyrin or 5,15-bis(<i>N</i> -methyl-4-pyridyl)-10,20-bis(4-pyridyl)porphyrin (55)
DMAP	-	4-(Dimethylamino)pyridine
DMSO	-	Dimethylsulfoxide
DNA	-	Deoxyribonucleic acid
DNases	-	Deoxyribonuclease
Et ₃ N	-	Triethylamine
FTIR	-	Fourier Transform Infrared Spectrometer
G ₄	-	Generation four
h	-	Hour
¹ H	-	Proton
IR	-	Infrared
<i>J</i>	-	Coupling constant
<i>m</i> -py	-	<i>meta</i> -Pyridyl
m	-	Multiplet

M	-	Molar
MeOH	-	Methanol
mg	-	Milligram
mL	-	Milliliter
mp	-	Melting point
MTT	-	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
N ₂	-	Nitrogen
NBS	-	<i>N</i> -bromosuccinimide
NCS	-	<i>N</i> -chlorosuccinimide
NHS	-	<i>N</i> -hydroxysuccinimide
nm	-	Nanometer
NMR	-	Nuclear Magnetic Resonance
<i>o</i> -py	-	<i>ortho</i> -Pyridyl
ODN	-	Oligodeoxyribonucleotide
OLED	-	Organic light emitting diode
PAMAM	-	Polyamidoamine
PDT	-	Photodynamic cancer therapy
PEI	-	Polyethylenimine
PLG	-	Poly(lactide-co-glycolide)
ppm	-	Part per million
PTSA	-	<i>p</i> -Toluenesulfonic acid
R _f	-	Retention factor
RNA	-	Ribonucleic acid
rt	-	Room temperature
SPSS	-	Statistical package for the social science version 16.0
STD	-	Standard deviation
TAPP	-	5,10,15,20-Tetrakis(4-acetamidophenyl)porphyrin (38)
TFA	-	Trifluoroacetic acid
THF	-	Tetrahydrofuran
TLC	-	Thin layer chromatography
TMPyCOPAMAM-	-	Cationic PAMAM G ₄ -porphyrin conjugate (64)
TMPyP4	-	<i>meso</i> -Tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin
TMPyHP2nd	-	5,10,15-Trihexyl-20-(<i>N</i> -methyl-4-pyridyl)porphyrin (60)

TMPyHP3rd	-	5,15-Dihexyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin	(61)
TMPyHP4th	-	5,10-Dihexyl-15,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin	(62)
TMPyHP5th	-	5-Hexyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl)porphyrin	(63)
TMPyP	-	5,10,15,20-Tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin	(17)
TMPyPP2nd	-	5,15-Dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin	(57)
TMPyPP3rd	-	5,10-Dipropyl-15,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin	(58)
TMPyPP4th	-	5-Propyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl)porphyrin	(59)
TPP	-	Tetraphenylporphyrin	
TriTMPyP	-	5,10,15-Tris(<i>N</i> -methyl-4-pyridyl)-20-(4-pyridyl)porphyrin	(56)
UV	-	Ultraviolet	
Zn(OAc) ₂	-	Zinc acetate	
q	-	Quartet	
s	-	Singlet	
t	-	Triplet	
v/v	-	Volume per volume	
μm	-	Micrometer	
μM	-	Micromolar	
μL	-	Microliter	
δ	-	Chemical shift	
λ	-	Lambda	
%	-	Percent	

LIST OF APPENDICES

APPENDIX	TITLE	PAGE
1	¹ H NMR of 5,10,15,20-tetraphenylporphyrin (6)	116
2	¹³ C NMR of 5,10,15,20-tetraphenylporphyrin (6)	117
3	UV-Vis Spectrum of 5,10,15,20-tetraphenylporphyrin (6)	118
4	IR Spectrum of 5,10,15,20-tetraphenylporphyrin (6)	119
5	¹ H NMR of 5,10,15,20-tetrakis(4-acetamidophenyl)porphyrin (38)	120
6	¹³ C NMR of 5,10,15,20-tetrakis(4-acetamidophenyl)porphyrin (38)	121
7	UV-Vis spectrum of 5,10,15,20-tetrakis(4-acetamidophenyl)porphyrin (38)	122
8	IR spectrum of 5,10,15,20-tetrakis(4-acetamidophenyl)porphyrin (38)	123
9	¹ H NMR of 5,10,15,20-tetrakis(4-pyridyl)porphyrin (15)	124
10	¹³ C NMR of 5,10,15,20-tetrakis(4-pyridyl)porphyrin (15)	125
11	UV-Vis spectrum of 5,10,15,20-tetrakis(4-pyridyl)porphyrin (15)	126
12	IR spectrum of 5,10,15,20-tetrakis(4-pyridyl)porphyrin (15)	127
13	¹ H NMR of 5-propyl-10,15,20-tris(4-pyridyl)porphyrin (39)	128
14	UV-Vis spectrum of 5,10-dipropyl-15,20-bis(4-pyridyl)porphyrin (42), 5,10,15,20-tetrakis(4-pyridyl)porphyrin (15), 5-propyl-10,15,20-tris(4-pyridyl)porphyrin (39) and 5,15-dipropyl-10,20-bis(4-pyridyl)porphyrin (41)	129
15	IR spectrum of 5-propyl-10,15,20-tris(4-pyridyl)porphyrin (39)	130
16	¹ H NMR of 5,15-dipropyl-10,20-bis(4-pyridyl)porphyrin (41)	131
17	¹ H NMR of 5,10-dipropyl-15,20-bis(4-pyridyl)porphyrin (42)	132
18	¹ H NMR of 5-hexyl-10,15,20-tris(4-pyridyl)porphyrin (43)	133
19	UV-Vis spectrum of 5,15-dihexyl-10,20-bis(4-pyridyl)porphyrin (46), 5,10-dihexyl-15,20-bis(4-pyridyl)porphyrin (47) and 5-hexyl-10,15,20-tris(4-pyridyl)porphyrin (43)	134

20	IR spectrum of 5-hexyl-10,15,20-tris(4-pyridyl)porphyrin (43)	135
21	¹ H NMR of 5,10,15-trihexyl-20-(4-pyridyl)porphyrin (45)	136
22	¹ H NMR of 5,15-dihexyl-10,20-bis(4-pyridyl)porphyrin (46)	137
23	IR spectrum of 5,15-dihexyl-10,20-bis(4-pyridyl)porphyrin (46)	138
24	¹ H NMR of 5,10-dihexyl-15,20-bis(4-pyridyl)porphyrin (47)	139
25	IR spectrum of 5,10-dihexyl-15,20-bis(4-pyridyl)porphyrin (47)	140
26	¹ H NMR of 5-(methoxycarbonylphenyl)-10,15,20-tris(4-pyridyl)porphyrin (48)	141
27	¹³ C NMR of 5-(methoxycarbonylphenyl)-10,15,20-tris(4-pyridyl)porphyrin (48)	142
28	UV-Vis spectrum of 5-(methoxycarbonylphenyl)-10,15,20-tris(4-pyridyl)porphyrin (48), 5,10-di(methoxycarbonylphenyl)-15,20-bis(4-pyridyl)porphyrin (52), 5,15-di(methoxycarbonylphenyl)-10,20-bis(4-pyridyl)porphyrin (51), 5,10,15-tri(methoxycarbonylphenyl)-20-(4-pyridyl)porphyrin (50)	143
29	IR spectrum of 5-(methoxycarbonylphenyl)-10,15,20-tris(4-pyridyl)porphyrin (48)	144
30	¹ H NMR of 5,10,15,20-tetra(methoxycarbonylphenyl)porphyrin (49)	145
31	IR spectrum of 5,10,15,20-tetra(methoxycarbonylphenyl)porphyrin (49)	146
32	¹ H NMR of 5,10,15-tri(methoxycarbonylphenyl)-20-(4-pyridyl)porphyrin (50)	147
33	IR spectrum of 5,10,15-tri(methoxycarbonylphenyl)-20-(4-pyridyl)porphyrin (50)	148
34	¹ H NMR of 5,15-di(methoxycarbonylphenyl)-10,20-bis(4-pyridyl)porphyrin (51)	149
35	IR spectrum of 5,15-di(methoxycarbonylphenyl)-10,20-bis(4-pyridyl)porphyrin (51)	150
36	¹ H NMR of 5,10-di(methoxycarbonylphenyl)-15,20-bis(4-pyridyl)porphyrin (52)	151
37	IR spectrum of 5,10-di(methoxycarbonylphenyl)-15,20-bis(4-pyridyl)porphyrin (52)	152
38	¹ H NMR of 5-(carboxyphenyl)-10,15,20-tris(4-pyridyl)porphyrin (53)	153

39	UV-Vis spectrum of PAMAM G ₄ , PAMAM G ₄ -porphyrin Conjugate (54), 5-(carboxyphenyl)-10,15,20-tris(4-pyridyl) porphyrin (53)	154
40	IR spectrum of 5-(carboxyphenyl)-10,15,20-tris(4-pyridyl) porphyrin (53)	155
41	¹ H NMR of PAMAM G ₄ -porphyrin conjugate (54)	156
42	¹³ C NMR of PAMAM G ₄ -porphyrin conjugate (54)	157
43	IR spectrum of PAMAM G ₄ -porphyrin conjugate (54)	158
44	¹ H NMR of PAMAM G ₄	159
45	¹ H NMR of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin (17)	160
46	¹ H- ¹ H COSY NMR of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl) porphyrin (17)	161
47	¹³ C NMR of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin (17)	162
48	UV-Vis spectrum of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl) porphyrin (17)	163
49	IR spectrum of 5,10,15,20-tetrakis(<i>N</i> -methyl-4-pyridyl)porphyrin (17)	164
50	¹ H NMR of 5,10-bis(<i>N</i> -methyl-4-pyridyl)-15,20-bis(4-pyridyl) porphyrin (55a) or 5,15-bis(<i>N</i> -methyl-4-pyridyl)-10,20-bis (4-pyridyl)porphyrin (55b)	165
51	UV-Vis spectrum of 5,10-bis(<i>N</i> -methyl-4-pyridyl)-15,20-bis(4-pyridyl)porphyrin (55a) or 5,15-bis(<i>N</i> -methyl-4-pyridyl)-10,20-bis (4-pyridyl)porphyrin (55b)	166
52	IR spectrum of 5,10-bis(<i>N</i> -methyl-4-pyridyl)-15,20-bis(4-pyridyl) porphyrin (55a) or 5,15-bis(<i>N</i> -methyl-4-pyridyl)-10,20-bis (4-pyridyl)porphyrin (55b)	167
53	¹ H NMR of 5,10,15-tris(<i>N</i> -methyl-4-pyridyl)-20-(4-pyridyl) porphyrin (56)	168
54	UV-Vis spectrum of 5,10,15-tris(<i>N</i> -methyl-4-pyridyl)-20-(4-pyridyl)porphyrin (56)	169
55	IR spectrum of 5,10,15-tris(<i>N</i> -methyl-4-pyridyl)-20-(4-pyridyl) Porphyrin (56)	170
56	¹ H NMR of 5,15-dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (57)	171

57	¹ H- ¹ H COSY NMR of 5,15-dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (57)	172
58	¹³ C NMR of 5,15-dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (57)	173
59	UV-Vis spectrum of 5-propyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl)porphyrin (59) , 5,15-dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (57), 5,10-dipropyl-15,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (58)	174
60	IR spectrum of 5,15-dipropyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (57)	175
61	¹ H NMR of 5,10-dipropyl-15,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (58)	176
62	¹³ C NMR of 5,10-dipropyl-15,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (58)	177
63	¹ H NMR of 5-propyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl)porphyrin(59)	178
64	IR spectrum of 5-propyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl)porphyrin (59)	179
65	¹ H NMR of 5,10,15-trihexyl-20-(<i>N</i> -methyl-4-pyridyl)porphyrin (60)	180
66	UV-Vis spectrum of 5,10,15-trihexyl-20-(<i>N</i> -methyl-4-pyridyl)porphyrin (60)	181
67	IR spectrum of 5,10,15-trihexyl-20-(<i>N</i> -methyl-4-pyridyl)porphyrin (60)	182
68	¹ H NMR of 5,15-dihexyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (61)	183
69	¹³ C NMR of 5,15-dihexyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (61)	184
70	UV-Vis spectrum of 5-hexyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl)porphyrin (63), 5,10-dihexyl-15,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (62), 5,15-dihexyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (61)	185
71	IR spectrum of 5,15-dihexyl-10,20-bis(<i>N</i> -methyl-4-pyridyl)porphyrin (61)	186

72	¹ H NMR of 5,10-dihexyl-15,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (62)	187
73	¹³ C NMR of 5,10-dihexyl-15,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (62)	188
74	IR spectrum of 5,10-dihexyl-15,20-bis(<i>N</i> -methyl-4-pyridyl) porphyrin (62)	189
75	¹ H NMR of 5-hexyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl) porphyrin (63)	190
76	¹³ C NMR of 5-hexyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl) porphyrin (63)	191
77	IR spectrum of 5-hexyl-10,15,20-tris(<i>N</i> -methyl-4-pyridyl) porphyrin (63)	192
78	¹ H NMR of cationic porphyrin-PAMAM (G ₄) conjugate (64)	193
79	¹³ C NMR of cationic porphyrin-PAMAM (G ₄) conjugate (64)	194
80	UV-Vis spectrum of cationic porphyrin-PAMAM (G ₄) conjugate (64)	195
81	IR spectrum of cationic porphyrin-PAMAM (G ₄) conjugate (64)	196
A	Cytotoxicity assay	197
B	ANOVA and Post Hoc Tests	203

CHAPTER 1

INTRODUCTION

1.1 Background of the Study

Porphyryns (1) are important cofactor that can be found in massive amounts of natural products such as chlorophyll (2) and hemin (3) [1]. They are the central regulatory effectors in many biochemical processes. Over- or underproduction of porphyryns will result in significant health problems ranging from mental illnesses like schizophrenia, leukemia to physical symptoms such as, port-coloured urine.




Figure 1.1: Structure of porphyrin (1), chlorophyll (2) and hemin (3)

Porphyryns can be accessed through laboratory synthesis and they are designed based on two porphyryns families; the β -substituted porphyryns that resemble naturally occurring porphyryns and the *meso*-substituted porphyryns. Porphyryns and their derivatives are usually synthesized based on condensation reactions between pyrroles and aldehyde derivatives since it represents a facile and straightforward synthetic method. Besides, different synthetic strategies also have been employed to obtain various porphyryns macrocycles. For example, MacDonald

reaction (2+2 acid-catalysed condensation) [2], Vilsmeier reaction, nucleophilic aromatic substitution reaction (S_NAr reaction) [3], electrophilic substitution reaction (S_EAr reaction) [4] and transition-metal catalysed reactions [5].

Porphyrins which consist of large aromatic macrocycles possess important chemical properties such as photochemical (energy and excitation transfer), redox (electron transfer, catalysis) [6] and coordination properties (metal and axial ligand binding) [7] which make these tetrapyrrole macrocycles play a crucial role in disparate areas like photodynamic cancer therapy [8-9], artificial photosynthesis [10], oxidation catalyst, sensors [11] and nanomaterial [12].

In addition, porphyrins and porphyrin-related macrocycles are found to have ability to bind to lysosomes, mitochondria and plasma membrane [8]. Cationic porphyrins have been reported for their ability to form strong electrostatic interaction with DNA [13] and used as nucleic acid transporting agents. For example, Kralova *et al.* reported that cationic porphyrin derivatives were efficient in transporting antisense oligodeoxyribonucleotides (ODNs) to primary leukemia cells [14]. Therefore, the electronic interaction with nucleic acids [15] and fluorescence properties has made porphyrins become promising delivery agents in gene therapy [16].

Gene therapy has been developed extensively as it provides a unique approach in treating both inherited and acquired disease. It involves the process of transferring genetic materials (DNA or RNA) into human cells to replace, correct or modify a mutated gene. To date, gene therapy has been shown as a successful tool to cure diseases such as, cystic fibrosis [17-18], severe combined immune deficiency (SCID) [19], haemophilia [20-21] and muscular dystrophies [22] as well as Parkinson disease [23]. Gene transfection process requires to surpass several barriers, starting from repulsion of negatively charged DNA by the negatively charged cell membrane, enzyme degradation of the DNA trafficks into endosome and finally internalization of the DNA through the nuclear pore into nucleus (**Figure 1.2**) [24]. Therefore, the gene delivery process has imposed formidable challenge to the development of gene therapy [14, 16].




Figure 1.2 Gene therapy [24]

Retroviruses and adenoviruses have been used as viral vectors in gene therapy that may present higher gene transfection efficiency compared to their non-viral counterparts. However, viral vectors may trigger specific immune response and under certain circumstance could result in death. Their clinical trials indicated several concerns, such as mutagenesis [24], inflammatory properties [25] and high cost [22]. On the other hand, cationic polymers such as, polyethylenimine (PEI), poly-L-lysine, cationic dendrimers and hydrophobic polymers such as poly(lactide-co-glycolide) (PLG) or polyanhydrides that form polyplexes with DNA are one of the primary non-viral vectors systems that have been examined for the optimization of gene delivery [26]. These cationic polymers give protection to DNA from deoxyribonuclease (DNases) degradation as well as enhancing the intracellular uptake [27]. However, the clinical trials of these non-viral delivery vectors are limited by the issues of transfection efficiency, biocompatibility [28], toxicity [29], low targeting specificity, cellular uptake and tend to aggregate in the blood [24].

These drawbacks have stimulated the search for non-viral gene carriers with high biocompatibility and cellular uptake but give low aggregation and minimal safety concern. In this study, various cationic porphyrin derivatives were synthesized and their cytotoxicity and intracellular uptake were tested as an evaluation for their potential uses as gene delivering agent.

1.2 Problem Statement

The success of gene therapy largely relies on the ability of gene delivery vectors to deliver nucleic acid into the targeted cells with minimal toxicity [25, 30]. About 70% of current gene therapies are using the viral method as the main gene-therapeutic protocols [27], but it is plagued by some serious health issues as well as inflammatory response [25]. On the other hand, non-viral vectors present the issue of toxicity [29], low biocompatibility [28], low cellular uptake as well as tend to aggregate in blood [24].

Porphyrins are interesting alternative to viral vector-mediated gene delivery. As they are essential compounds in most natural products, such as haemoglobin, porphyrins probably have higher biocompatibility with human body cells and thereby, avoiding immune response as induced by viral vectors. Besides, both hydrophilic and hydrophobic substituents can be directly anchored on the porphyrins macrocycle to increase their cell membrane penetration, which in turn, increase their cellular uptake. Whereas, most non-viral vectors require the incorporation of natural lipid molecules for exogenous DNA transportation into the cell through a biomimetic mechanism [29]. As highly hydrophobic substituents may cause extensive self-aggregation in aqueous solution [15], a shorter length of hydrocarbon such as, butanal and heptanal were employed as hydrophobic substituents in this study.

Besides, porphyrin molecules can strongly fluorescent which favor the location identification of vectors in the intracellular domain [16]. On the contrary, a fluorescent probe is required to attach on most other non-viral vectors' surfaces for the delivery process tracking. The introduction of the fluorescent probe may interrupt the physical or chemical properties of the gene vectors, giving an adverse effect on the biocompatibility and transfection efficiency [28].

In addition, there are abundant of chemical substituents can be covalently bonded to porphyrin macrocycles for particular nucleic acid or cell-type application [31]. Polyamidoamine (PAMAM) dendrimers which have shown high level of

transfection through a “proton sponge” mechanism can be conjugated with porphyrin to form a complex that may enhance transfection level with minimal toxicity effect.

In this study, various cationic porphyrin derivatives with different number, location and distribution of lipophilic and hydrophilic ligands along the peripheral of the macrocycle were synthesized using condensation method and low cost reagents. To evaluate their potential as gene carriers with minimal toxicity effect, their cytotoxicity and cellular uptake studies were conducted.

1.3 Objectives of the Study

The objectives of this study are:

1. To prepare and characterize basic cationic porphyrins.
2. To synthesis and characterize amphiphilic cationic porphyrin derivatives.
3. To synthesis and characterize cationic PAMAM-porphyrin conjugate.
4. To evaluate the cytotoxicity and cellular uptake of the cationic porphyrins as potential gene delivering reagents.

1.4 Scope of the Study

Condensation method was mainly employed in this study to synthesize diverse type of porphyrins. All cationic porphyrins were prepared using both methyl-*p*-toluenesulfonate and methyl iodide as the alkylation agents. Basic cationic porphyrin anchored with four cationic groups was synthesized. Besides, amphiphilic cationic porphyrins bearing different number of hydrophobic and hydrophilic substituents along the peripheral were also prepared in order to facilitate the penetration of gene carriers through the cell membrane. Polyamidoamine (PAMAM) dendrimer was also conjugated to porphyrins to produce a complex with improved cellular uptake and transfection level [32].

Cytotoxicity of the synthesized compounds towards the cells were conducted using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The assay was based on cleavage of yellow tetrazolium salt MTT to purple formazan by the metabolic active cells. In addition, cellular uptakes of the synthetic porphyrins were investigated in Chinese hamster ovary cells (CHO) and the qualitative results were obtained using inverted fluorescence microscope.

1.5 Significance of the Study

Porphyrins, as gene delivery agents may have a higher biocompatibility with human body cells as they are essential compounds in haemoglobin, thereby avoiding safety issue as triggered by viral vectors. Synthesis of amphiphilic cationic porphyrins give a better cell membrane permeability [33], which in turn producing a better cellular uptake. Self-aggregation is prevented when a shorter length of hydrocarbons were utilized as hydrophobic groups. Cationic PAMAM-porphyrin conjugate was also synthesized to enhance transfection level with minimal toxicity effect. In addition, the fluorescence properties of porphyrins contribute to the use of porphyrin as the marker candidate.

REFERENCES

1. Smith, K.M. Syntheses of Tetrapyrrole. In: Smith, A.G. and Witty, M. ed. *Heme, Chlorophyll, and Bilins: Methods and Protocols*. Humana Press: Totowa, NJ. 2002. 13-38.
2. Arsenault, G.P., Bullock, E. and MacDonald, S.F. Pyrromethanes and Porphyrins Therefrom. *Journal of American Chemical Society.*, 1960. 82(16): 4384-4389.
3. Horn, S., Dahms, K. and Senge, M.O. Synthetic Transformations of Porphyrins - Advances 2004-2007. *Journal of Porphyrins and Phthalocyanines*. 2008. 12: 1053-1077
4. Wiehe, A., Shaker, Y.M., Brandt, J.C., Mebs, S. and Senge, M.O. Lead Structures for Applications in Photodynamic Therapy. Part 1: Synthesis and Variation of m-THPC (Temoporfin) Related Amphiphilic A₂BC-type Porphyrins. *Tetrahedron*. 2005. 61: 5535-5564.
5. Bommer, J.C. and Hambright, P. General Laboratory Methods for Tetrapyrroles. In: Smith, A.G. and Witty, M. (Eds). *Heme, Chlorophyll, and Bilins: Methods and Protocols*. Totowa: Human Press, NJ. 2002.
6. Chirvony, V.S., Galievsky, V.A., Kruk, N.N., Dzhagarov, B.M. and Turpin, P-Y. Photophysics of Cationic 5,10,15,20-tetrakis(4-N-methylpyridyl) porphyrin Bound to DNA, [poly(dA-dT)]₂ and [poly(dG-dC)]₂: On a Possible Charge Transfer Process between Guanine and Porphyrin in Its Excited Singlet State. *Journal of Photochemistry and Photobiology B: Biology*. 1997. 40: 154-162.
7. Kelly, J.M. and Murphy, M.J. A Comparative Study of the Interaction of 5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin and Its Zinc Complex with DNA Using Fluorescence Spectroscopy and Topoisomerisation. *Nucleic Acids Research*. 1985. 13(1): 167-184.
8. Kramer-Marek, G., Serpa, C., Szurko, A., Widel, M., Sochanik, A., Sniatura, M., Kus, P., Nunes, R.M.D., Arnaut, L.G. and Ratuszna, A. Spectroscopic Properties and Photodynamic Effects of New Lipophilic Porphyrin

- Derivatives: Efficacy, Localisation and Cell Death Pathways. *Journal of Photochemistry and Photobiology B: Biology*. 2006. 84: 1-14.
9. Villanueva, A., Stockert, J.C., Canete, M. and Acedo, P. A New Protocol in Photodynamic Therapy: Enhanced Tumour Cell Death by Combining Two Different Photosensitizer. *Photochemical & Photobiological Science*. 2010. 9: 295-297.
 10. Lahtinen, R., Fermin, D.J., Kontturi, K. and Girault, H.H. Artificial Photosynthesis at Liquid/Liquid Interfaces: Photoreduction of Benzoquinone by Water Soluble Porphyrin Species. *Journal of Electroanalytical Chemistry*. 2000. 483: 81-87.
 11. Natale, C.D., Paollesse, R., Macagnano, A., Mantini, A., Mari, P. and D'Amico, A. Qualitative Structure - Sensitivity Relationship in Porphyrins Based QMB Chemical Sensors. *Sensors and Actuators B*. 2000. 68: 319-323.
 12. Shelnut, J.A., Wang, Z., Wang, H. and Meforth, J. Porphyrin-Based Nanostructures for Electronic Application. *Nanomaterial*. 32-33.
 13. Lipscomb, L.A., Fang, X.Z., Presnell, S.R., Woo, R.J., Peek, M.E., Plaskon, R.R. and Williams, L.D. Structure of a DNA-Porphyrin Complex. *Biochemistry*. 1996. 35: 2818-2823.
 14. Kralova, J., Dvorak, M. and Kral, V. Novel Cationic Transport Agents for Oligonucleotide Delivery into Primary Leukemic Cells. *Journal of Medicinal Chemistry*. 2003. 46: 2049-2056.
 15. Kubat, P., Lang, K., Anzenbacher, P.Jr., Jursikova, K., Kral, V. and Ehrenberg, B. Interaction of Novel Cationic meso-tetraphenylporphyrins in the Ground and Excited States with DNA and Nucleotides. *Journal of Chemical Society, Perkin Transaction*. 2000. 1: 933-941.
 16. Chaloin, L., Bigey, P., Loup, C., Marin, M., Galeotti, N., Piechaczyk, M., Heitz, F. and Meunier, B. Improvement of Porphyrin Cellular Delivery and Activity by Conjugation to a Carrier Peptide. *Bioconjugate Chemistry*. 2001. 12: 691-700.
 17. Ember, L., Added Gene Corrects Cystic Fibrosis Cells. *Chemical & Engineering News Archive*. 1990. 5a-6.
 18. Dagani, R., Big Step Toward Cystic Fibrosis Gene Therapy. *Chemical & Engineering News Archive*. 1992. 6.

19. Fischer, A., Salima, H.B.A. and Marina, C.C. Gene Therapy for Primary Adaptive Immune Deficiencies. *Journal of Allergy and Clinical Immunology*. 2011. 127(6): 1356-1359.
20. Dwarki, V.J., Belloni, P., Nijjar, T., Smith, J., Couto, L., Rabier, M., Clift, S., Berns, A. and Cohen, L.K. Gene Therapy for Hemophilia A: Production of Therapeutic Levels of Human Factor VIII in vivo in Mice. *Proceedings of National Academy of Science USA*. 1995. 1023-1027.
21. Habeck, M. New Approaches to Treating Haemophilia. *Molecular Medicine Today*. 2000. 214-215.
22. Rando, T.A. Non-Viral Gene Therapy for Duchenne Muscular Dystrophy: Progress and Challenges. *Biochimica et Biophysica Acta*. 2007. 1772: 263-271.
23. Rodnitzky, R.L. Upcoming Treatments in Parkinson's Disease, Including Gene therapy. *Parkinsonism and Related Disorders*. 2012. 18S1: S37-S40.
24. Liu, F. and Huang, L. Development of Non-Viral Vectors for Systemic Gene Delivery. *Journal of Controlled Release*. 2002. 78: 259-266.
25. Liu, Q. and Muruve, D. Molecular Basis of the Inflammatory Response to Adenovirus Vectors. *Gene Therapy*. 2003. 10: 935-940.
26. Pannier, A.K. and Shea, L.D. Controlled Release Systems for DNA Delivery. *Molecular Therapy*. 2004. 10(1): 19-26.
27. Taira, K., Kataoka, K. and Niidome, T. (Ed.) *Non-Viral Gene Therapy: Gene Design and Delivery*. Tokyo: Springer-Verlag. 2005.
28. Chen, Y., Zhou, L. Pang, Y., Huang, W., Qiu, F., Jiang, X., Zhu, X. Yan, D. and Chen, Q. Photoluminescent Hyperbranched Poly(amido amine) Containing β -Cyclodextrin as a Nonviral Gene Delivery Vector. *Bioconjugate Chemistry*. 2011. 22: 1162-1170.
29. Abbasi, M., Uludag, H., Olson, C., Lin, X., Clements, B.A., Rutkowski, D., Ghahary, A. and Weinfeld, M. Palmitic Acid-Modified Poly-L-Lysine for Non-Viral Delivery of Plasmid DNA to Skin Fibroblasts. *Biomacromolecules*. 2007. 8: 1059-1063.
30. Li, S. and Huang, L. Nonviral Gene Therapy: Promises and Challenges. *Gene Therapy*. 2000. 7: 31-34.

31. Flynn, S.M., George, S.T., White, L., Devonish, W. and Takle, G.B. Water-Soluble, Meso-Substituted Cationic Porphyrins - A Family of Compounds for Cellular Delivery of Oligonucleotide. *BioTechniques*. 1999. 26(4): 736-746.
32. Shieh, M-J., Peng, C-L., Lou, P-J., Chiu, C-H., Tsai, T-Y., Hsu, C-Y., Yeh, C-Y and Lai, P-S. Non-Toxic Phototriggered Gene Transfection by PAMAM-Porphyrin Conjugates. *Journal of Controlled Release*. 2008. 129: 200-206.
33. Lazzeri, D. and Durantini, E.N. Synthesis of meso-substituted Cationic Porphyrins as Potential Photodynamic Agents. *Archive for Organic Chemistry*. 2003: 227-239.
34. Grand, C.L., Han, H., Munoz, R.M., Weitman, S., Von Hoff, D.D., Hurley, L.H. and Bearss, D.J. The Cationic Porphyrin TMPyP4 Down-Regulates c-MYC and Human Telomerase Reverse Transcriptase Expression and Inhibits Tumor Growth in Vivo. *Molecular Cancer Therapeutics*. 2002. 1: 565-573.
35. Nagesh, N., Sharma, V.K., Kumar, G.A. and Lewis, E.A. Effect of Ionic Strength on Porphyrin Drugs Interaction with Quadruplex DNA Formed by the Promoter Region of C-myc and Bcl2 Oncogenes. *Journal of Nucleic Acids*. 2010. 2010: 1-9.
36. Yamashita, T., Uno, T. and Ishikawa, Y. Stabilization of Guanine Quadruplex DNA by the Binding of Porphyrins with Cationic Side Arms. *Bioorganic & Medical Chemistry*. 2005. 13: 2423-2430.
37. Anantha, N.V., Azam, M. and Sheardy, R.D. Porphyrin Binding to Quadruplexed T₄G₄. *Biochemistry*. 1998. 37: 1-9
38. Monnereau, C., Blart, E., Montembault, V., Fontaine, L. and Odobel, F. Synthesis of New Crosslinkable Co-Polymers Containing a Push-Pull Zinc Porphyrin for Non-Linear Optical Application. *Tetrahedron*. 2005. 61: 10113-10121.
39. Ryan, A., Tuffy, B., Horn, S., Blau, W.J. and Senge, M.O. Carbazole-Linked Porphyrin Dimers for Organic Light Emitting Diodes: Synthesis and Initial Photophysical Studies. *Tetrahedron*. 2011. 67: 8248-8254.
40. Milgrom, L. R. *The Colours of Life: An Introduction to Chemistry of Porphyrins and Related Compounds*. Oxford University Press. 1997.
41. Heltmann, E. (Ed.). *Journal of Chromatography Library, Vol. 22B*. In: *Chromatography: Fundamentals and Applications of Chromatographic and*

- Electrophoretic Methods. Part B: Applications. New York: Elsevier Science. 1983.
42. Smith, K.M. *General Features of the Structure and Chemistry of Porphyrin Compounds*. In: *Porphyryns and Metalloporphyryns*. Elsevier Scientific Publishing Company. 1975.
 43. Rothemund, P. Formation of Porphyrins from Pyrrole and Aldehydes. *Journal of American Chemical Society*. 1935. 57: 2010-2011.
 44. Adler, A.D. A Simplified Synthesis for meso-Tetraphenylporphin. *Journal of Organic Chemistry*, 1966. 32: 476.
 45. Lindsey, J.S. Synthetic Routes to meso-Patterned Porphyrins. *Account of Chemical Research*. 2009. 43(2): 300-311.
 46. Lee, C-H. and Lindsey, J.S. One-Flask Synthesis of Meso-Substituted Dipyrromethanes and Their Application in the Synthesis of Trans-Substituted Porphyrin Building Blocks. *Tetrahedron*. 1994. 50(39): 11427-11440.
 47. Rao, P.D., Dhanaleskshmi, S., Littler, B.J. and Lindsey, J.S. Rational Syntheses of Porphyrins Bearing Up to Four Different Substituents. *Journal of Organic Chemistry*. 2000. 65: 7323-7244.
 48. Hatscher, S. and Senge, M.O. Synthetic Access to 5,10-disubstituted Porphyrins. *Tetrahedron Letters*. 2003. 44: 157-160.
 49. Taniguchi, S., Hasegawa, H., Yanagiya, S., Tabeta, Y., Nakano, Y. and Takahashi, M. The First Isolation of Unsubstituted Porphyrinogen and Unsubstituted 21-Oxaporphyrinogen by the '3+1' Approach from 2,5-bis(hydroxymethyl)pyrrole and Tripyrrane Derivatives. *Tetrahedron*. 2001. 57: 2103-2108.
 50. Gryko, D. and Lindsey, J.S. Rational Synthesis of Meso-Substituted Porphyrins Bearing One Nitrogen Heterocyclic Group. *Journal of Organic Chemistry*. 2000. 65: 2249-2252.
 51. Monteiro, C.J.P., Pereira, M.M., Pinto, S.M.A., Simoes, A.V.C., Sa, G.F.F., Arnault, L.G., Formosinho, S.J., Simoes, S. and Wyatt, M.F. Synthesis of Amphiphilic Sulfonamide Halogenated Porphyrins: MALDI-TOFMS Characterization and Evaluation of 1-Octanol/Water Partition Coefficients. *Tetrahedron*. 2008. 64: 5132-5138.
 52. Borisov, S.M., Zenki, G. and Klimant, I. Phosphorescent Platinum(II) and Palladium(II) Complexes with Azatetrabenzoporphyrins - New Red Laser

- Diode - Compatible Indicators for Optical Oxygen Sensing. *Applied Materials & Interfaces*. 2010. 2(2): 366-374.
53. Hoffmann, P., Labat, G., Robert, A. and Meunier, B. Highly Selective Bromination of Tetramesitylporphyrin: An Easy Access to Robust Metalloporphyrins, M-Br₈TMP and M-Br₈TMPS. Examples of Application in Catalytic Oxygenation and Oxidation Reactions. *Tetrahedron Letters*. 1990. 31(14): 1991-1994.
 54. Ricchelli, F., Franchi, L., Miotto, G., Borsetto, L., Gobbo, S., Nikolov, P., Bommer, J.C. and Reddi E. Meso-Substituted Tetra-Cationic Porphyrins Photosensitize the Death of Human Fibrosarcoma Cells Via Lysosomal Targeting. *The Interanational Journal of Biochemistry & Cell Biology*. 2005. 37: 306-319.
 55. Wu, H.M., Pan, S.R., Chen, M.W., Wu, Y., Wang, C., Wen, Y.T., Zeng, X. and Wu, C.B. A Serum-Resistant Polyamidoamine-Based Polypeptide Dendrimer for Gene Transfection. *Biomaterial*. 2010: 1-16.
 56. Benimetskaya, L., Takle, G.B., Vilenchik, M., Lebedeva, I., Miller, P. and Stein, C.A. Cationic Porphyrins: Novel Delivery Vehicles for Antisense Oligodeoxynucleotides. *Nucleic Acids Research*. 1998. 26(23): 5310-5317.
 57. Wu, S., Li, Z., Ren, L., Chen, B., Liang, F., Zhou, X., Jia, T. and Cao, X. Dicationic Pyridium Porphyrins Appending Different Peripheral Substituents: Synthesis and Studies for Their Interactions with DNA. *Bioorganic & Medical Chemistry*. 2006. 14: 2956-2965.
 58. Jin, B., Lee, H.M., Lee, Y-A., Ko, J.H., Kim, C. and Kim, S.K. Simultaneous binding of *meso*-tetrakis(N-methylpyridinium-4-yl)porphyrin and 4',6-Diamidino-2-phenylindole at the minor Grooves of Poly(dA)·poly(dT) and Poly[d(A-T)₂]: Fluorescence Resonance Energy Transfer Between DNA Bound Drugs. *Journal of Chemical Society*. 2005. 127: 2417-2424.
 59. Peng, C.-L., Lai, P.-S., Chang, C.-C., Lou, P.-J. and Shieh, M.J. The Synthesis and Photodynamic Properties of meso-Substituted, Cationic Porphyrin Derivatives in HeLa Cells. *Dyes and Pigments*. 2010. 84: 140-147.
 60. Furgeson, D.Y. and Kim, S.W. Recent Advances in Poly(ethyleneimine) Gene Carrier Design. In: Svenson, S. (Ed.). *Polymeric Drug Delivery I*. Washington, DC.: American Chemical Society. 182-197. 2006.

61. Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., Behr, J-P. A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in vivo: Polyethylenimine. *Biochemistry*. 1995. 92: 7297-7301.
62. Esfand, R. and Tomalia, D.A. Poly(amidoamine) (PAMAM) Dendrimers: From Biomimicry to Drug Delivery and Biomedical Applications. *Drugs Discoveries & Therapeutics*. 2001. 6(8): 427-436.
63. Wolinsky, J.B. and Grinstaff, M.W. Therapeutic and Diagnostic Applications of Dendrimers for Cancer Treatment. *Advanced Drug Delivery Reviews*. 2008. 60: 1037-1055.
64. Kubat, P., Lang, K. and Zelinger, Z. Interaction of Porphyrins with PAMAM Dendrimers in Aqueous Solution. *Journal of Molecular Liquids*. 2007. 131-132: 200-205.
65. Astruc, D., Boisselier, E. and Ornelas, C. Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine. *Chemical Review*. 2010. 110: 1918-1920.
66. Tang, M.X., Redemann, C.T. and Szoka, F.C. Jr. In Vitro Gene Delivery by Degraded Polyamidoamine Dendrimers. *Bioconjugate Chemistry*. 1996. 7: 703-714.
67. Nouredini, S.C. and Curiel, D.T. Genetic Targeting Strategies for Adenovirus. *Molecular Pharmaceutics*. 2005. 2(5): 341-347.
68. Takae, Miyata, K., Oba, M., Ishii, T., Nishiyama, N., Itaka, K., Koyama, H. and Kataoka, K. PEG-Detachable Polyplex Micelles Based on Disulfide-Linked Block Cationomers as Bioresponsive Nonviral Gene Vectors. *Journal of American Chemical Society*. 2008. 130: 6001-6009.
69. Walters, L. and Anderson. Progress in Gene Therapy Brings Human Trials Near. *Chemical & Engineering News Archive*. 1984. 39-44.
70. Pavia, D.L., Lampman, G.M. and Kriz, G.S. *Introduction to Spectroscopy*. 3rd ed. United State of America: Thomson learning, Inc. 579. 2001
71. Littler, B.J., Miller, M.A., Hung, C-H., Wagner, R.W., O'Shea, D.F., Boyle, P.D. and Lindsey, J.S. Refined Synthesis of 5-Substituted Dipyrromethane. *Journal of Organic Chemistry*. 1999. 64:1391-1396

72. Gianferrara, T., Giust, D., Bratsos, L. and Alessio, E. Metalloporphyrins as Chemical Shift Reagents: The Unambiguous NMR Characterization of the cis- and trans-isomers of *meso*-(bis)-4'-pyridyl-(bis)-4'-carboxymethylphenyl porphyrins. *Tetrahedron*. 2007. 63: 5006-5013.
73. Sergeeva, N.N., Bakar, M.B. and Senge, M.O. Synthesis, Transformations, And Comparative Studies of Porphyrinyl Acrylic Acids And Their Homologues. *Journal of Organic Chemistry*. 2009. 74(4): 1488-1497.
74. Wade, L.G. *Organic Chemistry*. Pearson Prentice Hall. 2006.
75. Lau, S.Q. and Endud, S. *Iron (III) Porphyrin Dendrimer-Mesoporous Silica as Biomimetic Catalyst for Selective Oxidation of Trimethylphenol*. Universiti Teknologi Malaysia: Johor Bahru. 2009.
76. Vistica, D.T., Skehan, P., Scudiero, D., Monks, A., Pittman, A. and Boyd, M.R. Tetrazolium-Based Assays for Cellular Viability: A Critical Examination of Selected Parameters Affecting Formazan Production. *Cancer Research*. 1991. 51: 2515-2520.
77. Jayapal, K.P., Wlaschin, K.F., Hu, W-S. and Yap, M.G.S. Recombinant Protein Therapeutics from CHO Cells - 20 Years and Counting. *Chemical Engineering Progress*. 103. 2007. 10: 40-47.
78. Tjio, J.H. and Puck, T.T. Genetics of Somatic Mammalian Cells II. *The Journal of Experimental Medicine*. 1958. 108: 259-271.
79. Harcourt. *cellspd7spering Endocytosis-Exocytosis*, from <http://cellspd7spering.wikispaces.com/Endocytosis-Exocytosis>. 2001
80. Andria, R. Phospholipid Bilayer, from <http://newnurseblog.com/2011/04/04/4311/lipidbilayer/>.